1 Min Read
July 17 (Reuters) -
* Apexigen, Inc. Announces first patient dosed in phase 1b/2 clinical trial of apx005m in combination with opdivo (nivolumab) in advanced solid tumors Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.